Services on Demand
Journal
Article
Indicators
- Cited by SciELO
- Access statistics
Related links
- Cited by Google
- Similars in SciELO
- Similars in Google
Share
Revista Colombiana de Psiquiatría
Print version ISSN 0034-7450
Abstract
NUNEZ-GARCES, Marta; SANCHEZ-GAYANGO, Agustín and ROMERO-PEREZ, Cristina. Reversible Alopecia Secondary to OROS Methylphenidate. rev.colomb.psiquiatr. [online]. 2020, vol.49, n.3, pp.208-210. Epub Jan 17, 2021. ISSN 0034-7450. https://doi.org/10.1016/j.rcp.2018.09.003.
Introduction:
Attention deficit hyperactivity disorder has a prevalence of 1-4% of the Spanish school population. Its treatment consists of giving amphetamine derivatives and, recently, non-stimulant drugs, without finding any differences in efficacy in the studies performed.
Clinical case:
A 7-year-old girl was referred from neurology due to learning delay and behaviour disorders. Diagnosed as likely ADHD, treatment was started with immediate release methylphenidate, and later with an osmotic release oral system (OROS) methylphenidate. When alopecia areata appeared, this treatment was withdrawn. After the re-introduction of modified release methylphenidate 30:70, symptom control was achieved without the appearance of alopecia.
Discussion:
There is a published history of two cases of alopecia areata with OROS methylp henidate that resolved after increasing the dose of the drug without clearly knowing the reason for this event. There is no consensus on the priority use of the immediate release formula or the OROS methylphenidate.
Keywords : OROS methylphenidate; Alopecia areata; Side effects; ADHD.